title: Selection pressure on HIV-1 envelope by broadly neutralizing antibodies to the conserved CD4-binding site.
abstract: The monoclonal antibody (MAb) VRC01 was isolated from a slowly progressing HIV-1-infected donor and was shown to neutralize diverse HIV-1 strains by binding to the conserved CD4 binding site (CD4bs) of gp120. To better understand the virologic factors associated with such antibody development, we characterized HIV-1 envelope (Env) variants from this donor and five other donors who developed broadly neutralizing antibodies. A total of 473 env sequences were obtained by single-genome amplification, and 100 representative env clones were expressed and tested for entry and neutralization sensitivity. While VRC01 neutralizes about 90% of the genetically diverse heterologous HIV-1 strains tested, only selective archival Env variants from the VRC01 donor were sensitive to VRC01 and all of the Env variants derived from the donor plasma were resistant, indicating strong antibody-based selection pressure. Despite their resistance to this broadly reactive MAb that partially mimics CD4, all Env variants required CD4 for entry. Three other CD4bs MAbs from the same donor were able to neutralize some VRC01 escape variants, suggesting that CD4bs antibodies continued to evolve in response to viral escape. We also observed a relatively high percentage of VRC01-resistant Env clones in the plasma of four of five additional broadly neutralizing donors, suggesting the presence of CD4bs-directed neutralizing antibodies in these donors. In total, these data indicate that the CD4bs-directed neutralizing antibodies exert ongoing selection pressure on the conserved CD4bs epitope of HIV-1 Env.
authors.affiliation: Vaccine Research Center, NIAID, NIH, Bethesda, Maryland, USA.
authors.forename: Xueling
authors.initials: X
authors.lastname: Wu
authors.forename: Charlene
authors.initials: C
authors.lastname: Wang
authors.forename: Sijy
authors.initials: S
authors.lastname: O'Dell
authors.forename: Yuxing
authors.initials: Y
authors.lastname: Li
authors.forename: Brandon F
authors.initials: BF
authors.lastname: Keele
authors.forename: Zhongjia
authors.initials: Z
authors.lastname: Yang
authors.forename: Hiromi
authors.initials: H
authors.lastname: Imamichi
authors.forename: Nicole
authors.initials: N
authors.lastname: Doria-Rose
authors.forename: James A
authors.initials: JA
authors.lastname: Hoxie
authors.forename: Mark
authors.initials: M
authors.lastname: Connors
authors.forename: George M
authors.initials: GM
authors.lastname: Shaw
authors.forename: Richard T
authors.initials: RT
authors.lastname: Wyatt
authors.forename: John R
authors.initials: JR
authors.lastname: Mascola
mesh_terms: D000595:Amino Acid Sequence; D057134:Antibodies, Neutralizing / Q000276:immunology*; D001665:Binding Sites; D015704:CD4 Antigens / Q000737:chemistry / Q000276:immunology*; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology / Q000821:virology; D017124:Conserved Sequence; D015483:HIV Antibodies / Q000276:immunology*; D015699:HIV Envelope Protein gp120 / Q000737:chemistry / Q000235:genetics* / Q000276:immunology*; D015658:HIV Infections / Q000276:immunology / Q000821:virology*; D015497:HIV-1 / Q000737:chemistry / Q000145:classification / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008969:Molecular Sequence Data; D010802:Phylogeny; D012641:Selection, Genetic; D016415:Sequence Alignment
chemical_list: D057134:Antibodies, Neutralizing; D015704:CD4 Antigens; D015483:HIV Antibodies; D015699:HIV Envelope Protein gp120